InMed Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Sep 30, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 30, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| INMED PHARMACEUTICALS INC. | ||
| (Registrant) | ||
| September 27, 2024 | By: | /s/ Netta Jagpal |
|---|---|---|
| Netta Jagpal | ||
| Chief Financial Officer | ||
Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Eric A. Adams | President, Chief Executive Officer and Director | September 27, 2024 |
| Eric A. Adams | (Principal Executive Officer) | |
| /s/ Netta Jagpal | Interim Chief Financial Officer | September 27, 2024 |
| Netta Jagpal | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Andrew Hull | Director | September 27, 2024 |
| Andrew Hull | (Chairman to the Board of Directors) | |
| /s/ Janet Grove | Director | September 27, 2024 |
| Janet Grove | ||
| /s/ Bryan Baldasare | Director | September 27, 2024 |
| Bryan Baldasare | ||
| /s/ Nicole Lemerond | Director | September 27, 2024 |
| Nicole Lemerond | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.